Tassin F, Hermanne J P, Schaaf-Lafontaine N, Herens C, Thiry A, Paulus J M, Boniver J, Fillet G
Service d'Hématologie biologique, Université de Liège.
Rev Med Liege. 1998 Jun;53(6):357-62.
The myelodysplastic syndromes (MDS) are a heterogeneous group of disorders characterized by peripheral blood cytopenias with a hypercellular bone marrow exhibiting dyspoiesis. The predominant in elderly patients are associated with a high risk of progression to acute myelogenous leukemia. The etiology of MDS is unknown in most cases. About 10% of MDSs are secondary. MDS are classified by the French American British (FAB) classification into five subgroups. The incidence of the disorders is difficult to estimate but it seems to be increasing. Clonal cytogenetic aberrations are found in 30 to 50% of de novo MDS. The only currative treatment for MDS is allogeneic bone marrow transplantation.
骨髓增生异常综合征(MDS)是一组异质性疾病,其特征为外周血细胞减少,骨髓细胞增多并伴有发育异常。在老年患者中占主导地位,与进展为急性髓系白血病的高风险相关。在大多数情况下,MDS的病因尚不清楚。约10%的MDS是继发性的。MDS根据法美英(FAB)分类法分为五个亚组。这些疾病的发病率难以估计,但似乎在上升。30%至50%的原发性MDS存在克隆性细胞遗传学异常。MDS唯一的治愈性治疗方法是异基因骨髓移植。